Skadden is representing Valeant Pharmaceuticals in its $8.7 billion acquisition of Bausch & Lomb, announced on May 27.
Skadden is representing Valeant Pharmaceuticals in its $8.7 billion acquisition of Bausch & Lomb, announced on May 27.
